Adagene's Clinical Development Plan for Muzastotug
Adagene Inc. (NASDAQ: ADAG), a forward-thinking company dedicated to innovating antibody-based therapies, has some exciting news to share regarding its ongoing clinical efforts. After a constructive Type B meeting with the FDA, Adagene is gearing up to move forward with its clinical development plan for muzastotug (ADG126) in the treatment of microsatellite stable colorectal cancer (MSS CRC).
Phase 2 Trial Expectations
The company anticipates initiating patient enrollment for the Phase 2 trial in the latter half of 2025. This trial focuses on examining the efficacy and safety of muzastotug in combination with Merck's KEYTRUDA, administering ADG126 at either 10 mg/kg or 20 mg/kg. Each of these doses is part of a randomized approach aimed at determining the most effective strategy for future applications.
Key Highlights from the FDA Meeting
The FDA's feedback provided valuable insights into the future design of the trials, ensuring alignment on multiple critical aspects:
- Patient Selection: The upcoming trials will include late-line MSS CRC patients lacking liver metastases, expanding accessibility to those with peritoneal involvement.
- Dosing Strategy: The trial will feature a randomized assignment to 10 mg/kg or 20 mg/kg of ADG126 combined with pembrolizumab, focusing on an induction-maintenance regimen without strict limits on treatment cycles.
- Design of the Phase 2 Trial: Approximately 30 patients are expected to participate in each arm of the Phase 2 study, simplifying the focus on ADG126 without the need for a monotherapy arm.
- Phase 3 Planning: The FDA has confirmed that the designed standard-of-care (SOC) control arm for the Phase 3 trial does not necessitate an ADG126 monotherapy arm.
- Endpoints Identification: The primary endpoint for Phase 2 is the overall response rate (ORR), while key secondary endpoints will measure duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
- Phase 3 Trial Objectives: The primary focus will also be on OS for the Phase 3 study, with secondary endpoints mirroring those of the Phase 2 trial.
Promising Outcomes and Future Directions
Dr. Marwan Fakih, an eminent figure in medical oncology, highlighted the promising results from the FDA meeting, emphasizing the significant therapeutic window that ADG126 appears to offer. The discussion revealed a nearly two-fold increase in ORR, marking a notable advance in the treatment landscape for MSI CRC.
Peter Luo, Ph.D., the CEO and President of R&D at Adagene, expressed gratitude towards their strategic partner Merck for facilitating the provision of pembrolizumab. He conveyed optimism about the data collected thus far, reinforcing the company’s commitment to optimally progressing towards the Phase 2 segment of the clinical trial amid a landscape of evolving treatments for colorectal cancer.
About Adagene Inc.
Adagene Inc. is positioned at the forefront of antibody development, employing cutting-edge technology and strategic partnerships to create effective therapeutic options for cancer patients. Its SAFEbody platform, aimed at addressing challenges around safety and tolerability, offers a promising advancement in the realm of immunotherapy. With ongoing clinical investigations, particularly involving ADG126 in conjunction with established treatments, Adagene continues to forge ahead in changing the course of cancer care.
Frequently Asked Questions
What is muzastotug?
Muzastotug, or ADG126, is a novel masked anti-CTLA-4 SAFEbody designed by Adagene to target specific elements within the tumor microenvironment.
What is the significance of the FDA Type B meeting for Adagene?
The Type B meeting with the FDA provided crucial feedback, aligning on important aspects of the clinical trial's design, endpoints, and patient demographics for the Phase 2 trial.
When does Adagene plan to start enrolling patients for Phase 2 trials?
Adagene expects to begin enrolling patients for the Phase 2 trials in the latter half of 2025.
What are the primary objectives of the Phase 2 trial?
The main objective of the Phase 2 trial is to evaluate the overall response rate (ORR) to the treatment.
How does Adagene enhance the safety of its therapies?
Adagene employs SAFEbody technology that utilizes precision masking to minimize on-target off-tumor toxicity while concentrating therapeutic effects in the tumor environment.
